Healthcare / BiotechnologyHKSE
$4.14
-0.04 (-0.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-258.1M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.5B
P/E
24.4x
↑EV/EBITDA
19.5x
↑ROE
18.9%
↑Gross Margin
90.4%
↑Debt/Equity
0.77
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+291.6%
FCF CAGR
—
FCF margin
-14.1%
FCF / Net income
-0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $934.9M · net income $261.4M · FCF $-131.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $934.9M | $934.9M | $367.8M | $225.4M | $15.6M |
| Net Income | $261.4M | $261.4M | $-411.4M | $-22.1M | $-689.1M |
| EBITDA | $382.5M | $382.5M | $-302.4M | $86.9M | $-596.5M |
| EPS | 0.15 | 0.15 | -0.24 | -0.01 | -0.42 |
| Gross Margin | 90.4% | 90.4% | 79.7% | 87.5% | 87.1% |
| Operating Margin | 10.2% | 10.2% | -101.9% | -170.5% | -4123.9% |
| Net Margin | 28.0% | 28.0% | -111.8% | -9.8% | -4424.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.77 | 0.77 | 1.21 | 0.83 | 0.77 |
| Current Ratio | 0.98 | 0.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-131.4M | $-131.4M | $-258.1M | $-292.0M | $-596.4M |
| Returns | |||||
| ROE | 18.9% | 18.9% | -58.5% | -2.5% | -76.5% |
| Valuation | |||||
| P/E | 24.35 | 24.35 | — | — | — |
| EV/EBITDA | 19.55 | 19.55 | — | 74.69 | — |
| P/B | 5.24 | 5.24 | 6.04 | 6.88 | 13.39 |
| Growth & Yield | |||||
| Revenue Growth | 154.2% | 154.2% | 63.2% | 1347.2% | — |
| EPS Growth | 162.5% | 162.5% | -2300.0% | 97.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
34.8%
EPS terminal req.
$0.37
Spread vs growth
127.7%
5Y implied EPS CAGR
24.3%
EPS terminal req.
$0.44
Spread vs growth
138.2%
10Y implied EPS CAGR
16.9%
EPS terminal req.
$0.72
Spread vs growth
145.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.24 → 0.15
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.